FAT DEPOT-SPECIFIC REGULATION OF ENERGY METABOLISM
==================================================

Energy metabolism is crucial for the survival of living organisms. Metabolic homeostasis is tightly controlled by multiple endogenous and exogenous regulators \[[@B1][@B2][@B3][@B4][@B5][@B6]\]. Recently, accumulating evidence has suggested that adipose tissue is important for energy balance and endocrine functions by secreting various signaling molecules including adipokines, cytokines and lipokines \[[@B7][@B8][@B9][@B10][@B11]\]. In mammals, adipose tissue is spread throughout the body and is largely divided into white adipose tissue and brown adipose tissue which have their own functions ([Fig. 1A](#F1){ref-type="fig"}). Brown adipose tissue plays a key role in maintaining core body temperature by heat generation through uncoupling protein-1 (UCP-1) \[[@B12][@B13][@B14]\]. Since brown adipose tissue burns carbohydrates and lipid metabolites to produce heat, it has been recently considered as a potential target to treat obesity and metabolic complications. However, we will not consider brown and beige adipose tissue, which have been addressed in numerous other review papers. Instead, we will focus on heterogeneous characters of white adipose tissue in this review \[[@B12][@B15][@B16][@B17]\]. Unlike brown adipose tissue, white adipose tissue is a prominent energy reservoir and can be anatomically categorized into subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) ([Fig. 1A](#F1){ref-type="fig"}). SAT is localized under the dermal layers where it protects against physical damage and insulates the body from cold environments. VAT is located in the intra-abdominal cavity and is able to dynamically communicate with other internal organs due to their physical proximity. Since both SAT and VAT are morphologically similar, it has been considered that SAT and VAT may have the same functions with similar or identical adipogenic progenitors (APs). It has been reported that both SAT and VAT appear to originate from myogenic factor 5 (Myf5^−^) mesenchymal/mesodermal cells during development \[[@B18][@B19]\]. Nonetheless, recent studies have shown that several characteristics of SAT and VAT are distinct in aspects of metabolic regulation ([Figs. 1B](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). For instance, in obese humans, expanded VAT is highly correlated with elevated susceptibility of metabolic disorders. However, this correlation is not observed in obese people with expanded SAT \[[@B20][@B21][@B22]\]. Moreover, it has been reported that metabolic parameters of obese patients with a higher proportion of SAT are closer to the normal range \[[@B23][@B24][@B25]\]. Although accumulating evidence suggests that metabolic characteristics between SAT and VAT are different \[[@B20][@B26][@B27][@B28]\], it is unclear whether distinct metabolic responses and regulation in VAT and SAT would be a simple correlation or causal relationship. To address this issue, rodent models including mice and rats have been subjected to be investigated. For example, fat tissue transplantation experiments in obese mice have provided direct evidence that SAT is metabolically beneficial. In obese mice, intra-abdominal transplantation of SAT downregulates body weight gain and ameliorates insulin resistance and glucose intolerance \[[@B29][@B30]\]. On the other hand, surgical removal of VAT alleviates metabolic complications in rat \[[@B31]\]. A very recent study reported that transplanted donor fat tissue from obese mice retain their intrinsic inflammatory characteristics in obese mice \[[@B32]\]. These collective findings have supported that SAT and VAT would have their own causal factor(s) to exhibit the different metabolic regulation.

DIFFERENT ADIPOGENIC CHARACTERISTICS BETWEEN SAT AND VAT
========================================================

In adipose tissue, the adipogenic capacity from progenitor cells is closely associated with metabolic changes. In obesity, hypertrophic adipocytes (enlarged adipocytes) are frequently observed in VAT. These hypertrophic adipocytes contribute to systemic insulin resistance \[[@B33][@B34]\]. In contrast, small and multilocular adipocytes exhibit increased glucose-uptake upon exposure to insulin compared to hypertrophic and unilocular adipocytes \[[@B33][@B35]\]. Moreover, genetically obese mice that feature increased numbers of adipocytes (adipocyte hyperplasia) in SAT are relatively insulin sensitive and maintain a normal range of metabolic parameters \[[@B36]\]. Obese but metabolically healthy humans tend to be biased towards a higher proportion of SAT with enhanced adipocyte hyperplasia \[[@B23][@B24][@B25]\]. Consistently, in obese patients, increased adipogenesis due to treatment with the thiazolidinedione, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, alleviates metabolic disorders by improving insulin sensitivity, accompanied with increased SAT \[[@B37][@B38][@B39]\].

By treating with collagenase, adipose tissue can be largely separated into differentiated adipocytes and stromal vascular cells (SVCs). SVCs are composed of heterogeneous cell populations including endothelial cells, immune cells, fibrocytes, and APs that can potentially differentiate into adipocytes in the presence of adipogenic stimuli, including insulin-like growth factor-1 and glucocorticoids \[[@B9][@B19]\]. Differentiation of APs into mature adipocytes is governed by key adipogenic transcription factors such as PPARγ, CCAAT/enhancer binding proteins (C/EBPs), and sterol-regulatory element binding protein 1c (SREBP1c) \[[@B40][@B41][@B42][@B43]\]. Fully differentiated adipocytes from SAT and VAT highly express adipogenic and lipogenic genes. Nonetheless, it seems that the adipogenic capacity differs between SAT and VAT in the presence of particular cues. APs isolated from SAT and VAT differ in their degree of adipocyte differentiation under adipogenic culture conditions \[[@B44][@B45]\]. Under *ex vivo* cell culture conditions, APs from SAT are more adipogenic than those from VAT \[[@B34]\]. Furthermore, obese patients treated with thiazolidinedione show expansion of SAT with hyperplasia of small adipocytes while VAT mass is relatively reduced \[[@B37][@B38]\]. The data from *ex vivo* cell culture conditions have been challenged by *in vivo* studies utilizing mouse lineage tracing systems \[[@B46][@B47]\]. Upon high-fat diet (HFD) feeding, the proliferation of APs from VAT is greatly increased within 3 days. These proliferating APs differentiate into adipocytes whereas APs from obese SAT do not rapidly proliferate \[[@B47]\]. The inconsistency between *in vivo* animal experimental data and *ex vivo* cell culture data make it plausible to speculate that the different adipogenic potentials of SAT and VAT could reflect either tissue environmental cues or intrinsically different characteristics of APs from each fat depot. In particular, given that comparisons of the adipogenic potential during *ex vivo* cell culture excluding tissue environmental niche are different between SAT and VAT, it appears that APs from SAT and VAT could have their own intrinsic characteristics. Thus, it is possible that the developmental origins or ancestral cellular lineages of APs in SAT and VAT might not be the same population. For instance, it has been demonstrated that VAT is preferentially enriched with mesothelial APs \[[@B48][@B49]\]. On the other hand, there is a high abundance of APs that express dipeptidyl protease 4 (DPP4) in SAT \[[@B50]\]. Moreover, recent studies with single cell RNA-seq analysis from stromal cells without immune and endothelial cells have shown that APs of SAT and VAT would have different transcriptomic features \[[@B50][@B51][@B52]\]. These recent findings indicate that developmentally different adipogenic potentials in SAT and VAT would be one of the key intrinsic factors to determine its own roles on metabolic regulation in obesity.

IMMUNOMODULATORY ROLES OF DEPOT-SPECIFIC AP IN SAT AND VAT
==========================================================

In the early 1990s, it was reported that the tumor necrosis factor α, an inflammatory cytokine, is synthesized and secreted in adipose tissue \[[@B53]\]. This finding prompted the investigation of inflammatory responses in adipose tissue due to their strong association with metabolic dysregulation in obesity ([Fig. 3](#F3){ref-type="fig"}) \[[@B7][@B54][@B55][@B56]\]. In lean fat tissue, anti-inflammatory cells such as regulatory T-cells, eosinophils, and invariant natural killer T (iNKT) cells play crucial roles to maintain adipose tissue homeostasis \[[@B57][@B58][@B59][@B60][@B61][@B62][@B63][@B64][@B65]\]. In obese adipose tissue, various pro-inflammatory immune cells such as macrophages, neutrophils, cytotoxic T cells, and B cells are recruited and prevail against anti-inflammatory cells to increase pro-inflammatory responses in obesity \[[@B27][@B66][@B67][@B68][@B69][@B70]\]. Elevated inflammatory responses by pro-inflammatory immune cells disrupt metabolic homeostasis by augmenting fibrosis, oxidative stress, and insulin resistance in obese adipose tissue \[[@B71][@B72][@B73][@B74][@B75]\]. Moreover, pro-inflammatory immune cells not only impair insulin signaling, but also dysregulate normal lipid metabolism in obesity \[[@B66][@B76]\]. Of note, VAT is prone to be pro-inflammatory, whereas SAT is less susceptible to inflammatory responses in obesity ([Fig. 4](#F4){ref-type="fig"}) \[[@B27][@B77]\]. In a mouse model, macrophage infiltration is rapidly increased in VAT upon HFD feeding \[[@B78]\]. However, such effects are rarely observed in obese SAT \[[@B26][@B27][@B32][@B79]\]. It has been proposed that certain cell types in adipose SVCs in obese VAT contribute to the aggravation of pro-inflammation. In obese VAT, increased fibrosis interrupts normal metabolic functions and elevates inflammatory responses \[[@B71][@B80]\]. Moreover, it has been reported that adipose tissue fibrosis induced by obesity is mediated by APs expressing both platelet-derived growth factor receptor α (PDGFRα) and high level of cluster of differentiation 9 (CD9) \[[@B81][@B82]\]. Although these fibrotic APs still express AP marker genes such as CD34, stem cell antigen-1 (Sca-1), and PDGFRs, their adipogenic potential is diminished \[[@B82][@B83]\]. Furthermore, these obesity-induced fibrotic APs stimulate expressions of pro-inflammatory genes and inhibit adipogenesis in VAT \[[@B83]\]. These results imply that APs in obese VAT would contribute to aggravation of adipose tissue dysfunction and metabolic dysregulation. On the other hand, the number of these cell populations in SAT are significantly lower than VAT \[[@B32]\]. In addition, intra-abdominal transplantation of SAT alleviates systemic inflammatory responses and insulin resistance in obese mice \[[@B30][@B32]\], implying that certain factors of SAT have anti-inflammatory roles in obesity. Furthermore, it has been shown that gamma-aminobutyric acid (GABA) signaling in SAT is crucial in suppressing SAT inflammation in obesity \[[@B32]\]. GABA is an inhibitory neurotransmitter in the central nervous system \[[@B84][@B85]\]. Although GABA concentration in peripheral tissues is lower than in the central nervous system, SAT is able to synthesize and stabilize GABA (approximately 5 to 20 nmol/g tissue) compared to VAT \[[@B32]\]. More importantly, it has been demonstrated that the anti-inflammatory cell type responding to GABA is APs rather than other immune cells, in SAT \[[@B32]\]. Although the underlying mechanisms by which APs from SAT and VAT could differentially regulate fat depot-specific inflammatory responses in obesity are still unclear, these findings open the door to emphasize fat depot-specific and immunomodulatory roles of APs in the regulation of energy metabolism in obesity.

FAT DEPOT-SELECTIVE HETEROGENEOUS AP AND THEIR MARKERS
======================================================

In mammalian development, adipocytes are derived from mesenchyme/mesoderm \[[@B19]\]. Although bone marrow has been reported as a source of APs due to its enriched pools of mesenchymal stem cells \[[@B86]\], recent *in vivo* mouse lineage tracing systems have revealed that APs in adult animals reside in the adipose perivascular region \[[@B45][@B46]\]. Several groups have reported that numerous genes such as CD31, CD45, leukocyte antigen 76/TER-119, PDGFRα, PDGFRβ, CD24, CD34, Sca-1, DPP4, and intercellular adhesion molecule-1 (ICAM-1), are potential surface markers for APs ([Table 1](#T1){ref-type="table"}) \[[@B44][@B45][@B50][@B52][@B87][@B88][@B89]\]. However, several lines of evidence have suggested that the surface marker genes mentioned above are insufficient to pinpoint or isolate pure APs. Firstly, fibrotic APs still express adipogenic surface markers despite the loss of their potential to differentiate into adipocytes \[[@B81][@B82][@B90]\]. Secondly, APs isolated from SAT and VAT using aforementioned surface markers show different functional outcomes in many aspects that include fibrosis, adipogenesis, vascularization, and inflammation \[[@B32][@B50][@B51][@B91][@B92]\]. Moreover, single cell RNA sequencing analyses has shown that isolated APs with adipogenic surface markers exhibit heterogeneous cell populations in different white adipose tissues \[[@B51][@B52][@B83]\]. In particular, single-cell transcriptome features of APs from SAT are different from VAT. It has been recently reported that SAT has more abundant DPP4 positive APs than VAT \[[@B50]\]. Due to their multipotency, it has been proposed that DPP4 positive APs could be a progenitor cell type of ICAM-1 or CD142 positive APs which are more committed cell type of APs. Nevertheless, the adipogenic potential of CD142 positive AP is still controversial \[[@B52]\]. For example, it has been shown that CD142 and ATP-binding cassette subfamily G (ABCG1) double-positive stromal cell is a suppressive cell type of adipogenesis \[[@B52]\]. Thus, further studies are evidently needed to identify more precise cellular markers to elucidate fat depot-specific roles from various subpopulations of APs.

CONCLUSIONS
===========

In this review, we have discussed that several white adipose tissues have distinct characteristics depending on their anatomical locations and differential responses to nutritional status. Depending on the anatomical location of adipose tissue, adipogenesis relies on the tissue niche, whereas differential immune responses between fat depots are affected by intrinsic characteristics, rather than by environmental factors \[[@B32][@B89]\]. Accumulating data from latest technologies including single-cell RNA sequencing analyses and lineage tracing mouse models have shown that APs from SAT and VAT have distinct and heterogeneous gene expression profiles. Moreover, it is very likely that APs from SAT and VAT mediate different adipogenic and immunomodulatory functions in obesity. APs from VAT are more adipogenic and pro-inflammatory whereas APs from SAT have more progenitor cell types of APs (DPP4^+^ APs) and are anti-inflammatory. These differences in SAT and VAT could differentially contribute to metabolic regulation, indicating that APs would be one of the key factors in fat tissue development and whole body metabolism. According to these heterogeneities between SAT and VAT, it is feasible to assume that subcutaneous and visceral APs would have different developmental origins despite their similarities in tissue morphology. Taken together, understanding fat depot-specific adipogenesis and relationship between APs and adipose tissue immunity will shed new light on metabolic and stem cell research area in the future.
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![Adipose tissue distribution in human and heterogeneous characteristics between subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese mice. (A) In human, adipose tissues are found in areas all over the body. In particular, brown adipose tissue is localized in neck, shoulder, and thorax to generate heat via higher activity of mitochondria and uncoupling protein-1 (UCP-1). VAT is localized in intra-abdomen and SAT is spread throughout the whole body. Both SAT and VAT have a higher capacity for lipid storage than brown adipose tissue. (B) In obese mice, SAT and VAT are differentially respond to obesity in many aspects such as immune responses, adipogenesis, and vasculatures. In obese mice, VAT exhibit elevated fibrosis and inflammatory responses accompanied with increased *in vivo* adipogenic potential. In contrast, such effects were rarely observed in obese SAT. Moreover, prolonged obesity reduces vasculature in obese VAT, whereas vasculature in obese SAT is denser than that in obese VAT.](dmj-43-752-g001){#F1}

![Dissimilarity of vascularization and angiogenesis in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) upon high-fat diet (HFD) feeding. Endothelial cells were stained with CD31 antibody conjugated with fluorescein isothiocyanate (FITC) fluorescence. Upon HFD feeding, vascular structures of visceral epididymal adipose tissue (EAT) are dramatically reduced compared to normal chow diet (NCD) fed mice. However, subcutaneous inguinal adipose tissue (IAT) in obesity maintains a similar degree of vasculatures compared to IAT in NCD condition. Scale bar indicates 100 µm.](dmj-43-752-g002){#F2}

![Immune cells and pro-inflammatory responses in obesity. Normal and healthy adipose tissue harbors various types of anti-inflammatory immune cells such as M2-like macrophages (M2 MAC), eosinophils, helper T type 2 (T~H~2) cells, regulatory T (Treg) cells, and invariant natural killer T (iNKT) cells. These immune cells are involved in maintaining normal adipose functions and insulin sensitivity. In obesity, the number of pro-inflammatory immune cells including neutrophil, M1-like macrophages (M1 MAC), neutrophils, helper T type 1 (T~H~1) cells, Cytotoxic T (Tc) cells, and natural killer (NK) cells are elevated. In parallel, anti-inflammatory immune cells are decreased, leading to aggravation of adipose tissue inflammation and adipose dysfunction.](dmj-43-752-g003){#F3}

![Subcutaneous and visceral adipogenic progenitors (APs) differentially respond to obesity and exert opposite effects on adipose tissue inflammation. Visceral APs are composed of mesothelial and mesodermal cells, but a certain portion of these cells lose adipogenic potential and are transformed into pro-inflammatory fibrocytes in obesity. The fibrotic-APs in visceral adipose tissue (VAT) exacerbate adipose tissue inflammation via inducing fibrosis and secreting pro-inflammatory cytokines. On the other hand, subcutaneous APs suppress pro-inflammatory macrophage infiltration into subcutaneous adipose tissue (SAT) in response to gamma-aminobutyric acid (GABA). Consequently, these anti-inflammatory effects on SAT would contribute to improvement of energy metabolism in obesity.](dmj-43-752-g004){#F4}

###### A list of surface marker genes identified for APs

![](dmj-43-752-i001)

  Gene                                                      Discovery and identification                            Remark                                                        Reference
  --------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------
  CD10/NEP/cALLA                                            Hematopoietic stem cells and mesenchymal tumour cells   Alternative marker for mesenchymal stem cells                 Br J Haematol 1994;87:655-7
  Arthritis Rheum 2002;46:3349-60                                                                                                                                                 
  Ann N Y Acad Sci 2007;1106:262-71                                                                                                                                               
  Mod Pathol 2002;15:923-30                                                                                                                                                       
  CD73/NT5E                                                 Placenta                                                Mesenchymal stem cell marker                                  Eur J Biochem 1990;191:563-9
  Cytotherapy 2006;8:315-7                                                                                                                                                        
  CD90/Thy-1                                                Thymocytes                                              Mesenchymal and hematopoietic stem cell marker                J Exp Med 1964;120:413-33
  Am J Physiol Gastrointest Liver Physiol 2006;291:G45-54                                                                                                                         
  CD105/Endoglin                                            Mesenchymal stem cells                                  Mesenchymal stem cell marker                                  Biochem Biophys Res Commun 1999;265:134-9
  CD31/PECAM-1                                              Endothelial cells                                       Negative surface marker staining endothelial cell             Science 1990;247:1219-22
  Cell 2008;135:240-9                                                                                                                                                             
  CD45/LCA                                                  Hematopoietic stem cells                                Negative surface marker staining hematopoietic immune cells   Annu Rev Immunol 2003;21:107-37
  Science 2008;322:583-6                                                                                                                                                          
  Cell 2008;135:240-9                                                                                                                                                             
  Ter119/Ly-76                                              Bone marrow cells                                       Negative surface marker staining hematopoietic immune cells   Cell 1990;62:863-74
  Blood 2000;95:2559-68                                                                                                                                                           
  Diabetes 2012;61:1691-9                                                                                                                                                         
  Science 2008;322:583-6                                                                                                                                                          
  CD34                                                      Hematopoietic stem cells                                AP marker, but not mesenchymal stem cell marker               J Immunol 1992;148:267-71
  Cell 2008;135:240-9                                                                                                                                                             
  Science 2008;322:583-6                                                                                                                                                          
  Sca-1/Ly6a                                                Hematopoietic stem cells                                AP marker                                                     Mol Cell Biol 1990;10:5150-9
  Cell 2008;135:240-9                                                                                                                                                             
  Science 2008;322:583-6                                                                                                                                                          
  PDGFRα                                                    APs                                                     AP marker                                                     Cell Metab 2012;15:480-91
  Cell Metab 2013;18:355-67                                                                                                                                                       
  PDGFRβ                                                    Perivascular cells                                      AP marker                                                     Science 2008;322:583-6
  Elife 2018;7:e39636                                                                                                                                                             
  CD24                                                      Adipose stromal cells                                   AP marker                                                     Cell 2008;135:240-9
  DPP4                                                      Adipose stromal cells                                   Progenitor cell type marker of AP                             Science 2019;364:eaav2501
  ICAM-1                                                    Adipose stromal cells                                   AP marker                                                     Science 2019;364:eaav2501

CD10, cluster of differentiation 10; NEP, neutral endopeptidase; cALLA, common acute lymphoblastic leukemiaantigen; NT5E, ecto-5′-nucleotidase; Thy-1, thymus cell antigen 1; PECAM-1, platelet endothelial cell adhesion molecule 1; LCA, leukocyte common antigen; Ly-76, lymphocyte antigen-76; AP, adipogenic progenitor; Sca-1, stem cell antigen 1; Ly6a, lymphocyte antigen-6a; PDGFR, platelet-derived growth factor receptor; DPP4, dipeptidyl protease 4; ICAM-1, intercellular adhesion molecule-1.
